Daniel Rabinowitz, Secretary and Legal Director of Natera, Inc. (NASDAQ:NTRA), recently sold a significant portion of its holdings in the company. The sale comes as Natera stock trades near its 52-week high of $177, having generated an impressive 177.73% return over the past year. With a market capitalization of $23.14 billion, the company maintains a good financial health score according to InvestingPro analysis. According to a filing with the Securities and Exchange Commission, Rabinovich sold 6,223 shares of common stock on January 8, 2025. The shares were sold at a weighted average price of $175.3015, generating total consideration of approximately $1,090,901.
This transaction was executed as part of a pre-arranged trading plan under Rule 10b5-1, which Rabinovich adopted on June 14, 2024. Following the sale, Rabinovich retains direct ownership of 199,804 shares in the Company.
In other recent news, Natera Company (Nasdaq:). It expanded its patent infringement suit against NeoGenomics (NASDAQ:) over RaDaR, a test for residual molecular diseases. The company reported record third-quarter revenue of $439.8 million, representing a 64% year-over-year increase, and performed 137,000 oncology tests, an increase of 54% from the previous year. Amid these developments, TD Cowen, Baird and Jefferies maintained positive ratings on Natera stock and raised their price targets.
Natera also faced a setback in a false advertising lawsuit against it Guardian health (NASDAQ:), but plans to ask the court to overturn the ruling. In addition, the Company has amended an agreement with Dr. Rabinowitz, Executive Chairman of the Board of Directors, to continue in his role on the terms set forth in the agreement.
These latest developments provide investors with insight into Natera's current position. The company continues to strengthen its position in the genetic testing industry, despite facing legal challenges and the competitive landscape.
This article was created with the power of artificial intelligence and reviewed by an editor. For more information, see our terms and conditions.
